How hormones and seasons shape alpha-1 and its impact on health

After analysing 20,000 patient records, RCSI researchers and the Alpha-1 Foundation Ireland have uncovered new insights into how the immune system behaves in people both with and without AATD.

Worrying rise in self-harm among adolescents, with trans, gender diverse and early school leavers most at risk

Researchers in RCSI and King’s College London have found that while rates of poor mental health and suicide attempts among Irish adolescents have fallen from pandemic peaks, repeated self-harm is increasing.

RCSI researchers develop RNA-activated implant to stimulate nerve regrowth after spinal cord injury

Researchers from RCSI have developed a novel implant that delivers therapeutic RNA via engineered nanoparticles directly to injured nerve cells, offering a new approach to stimulating neuron regeneration after spinal cord injury.

RCSI partners in ARC Hub for MedTech and ARC Hub for Therapeutics

RCSI has joined as a partner institution in the two newly launched ARC Hubs for Therapeutics and for MedTech, both part of Research Ireland’s flagship Accelerating Research to Commercialisation (ARC) Programme.

New research finds spike in spinal cord damage among Irish teens linked to nitrous oxide use

A new study led by Professor Seamus Looby of RCSI and Beaumont Hospital has revealed that young people in Ireland are increasingly being diagnosed with spinal cord damage from recreational use of nitrous oxide.

Professor Gianpiero Cavalleri appointed to Ireland’s National Science Advice Forum 

RCSI and FutureNeuro's Professor Gianpiero Cavalleri has been appointed to Ireland’s new National Science Advice Forum, which comprises 12 members with internationally recognised expertise across a range of scientific disciplines.

RCSI researcher awarded ERC Consolidator Grant to develop bone cancer therapies

RCSI's Dr Caroline Curtin has been awarded a prestigious European Research Council (ERC) Consolidator Grant of €2 million to develop a novel technology that will revolutionise the treatment of primary bone cancers.